EMBL Ventures
EMBL Ventures is a German venture capital engaged in the financing and development of products and technologies in the healthcare sector.
Business Model:
Revenue: $17.4M
Employees: 2-10
Rankings
Industries / Tags:
Detailed EMBL Ventures Information
Geographic Data
Address: Boxbergring 107
City: Heidelberg
State: baden-württemberg
Zip: 69126
Country: DE
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
EMBL Ventures is a German venture capital engaged in the financing and development of products and technologies in the healthcare sector. EMBL Ventures manages three Funds with a total of 120m capital on behalf of major European private and institutional investors. We prefer a role as lead or co-lead investor in financing rounds which typically range from 5m to 40m. Our total commitment in a single portfolio company can go as high as 10m. As with our portfolio companies each Partner at EMBL Ventures strives to build long-lasting personal relationships with Investors in our Funds, such as institutionals, high net-worth individuals and family offices. These relationships are based on EMBL Ventures&s; core values of open and prompt communication coupled with the ambition to generate maximum return.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2006 | Vasopharm | Series B | 0 |
| 10/2013 | Opsona | Series C | 0 |
| 4/2014 | Crescendo Biologics | Series A | 3.3M |
| 4/2013 | Opsona | Series C | 0 |
| 3/2016 | Topas Therapeutics | Series A | 0 |
| 4/2017 | Arsanis | Series D | 0 |
| 6/2015 | Vira Therapeutics | Series A | 4M |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 10/2014 | ImevaX | Series A | 0 |
| 4/2006 | Endoart | Series C | 0 |
| 2/2004 | immatics biotechnologies | Series A | 0 |
| 4/2018 | Crescendo Biologics | Series B | 0 |
| 10/2015 | Luxendo | Series A | 0 |
| 10/2005 | Affectis Pharmaceuticals | Series B | 4.8M |
| 11/2009 | ELARA Pharmaceuticals | Series A | 6.9M |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 1/2017 | Luxendo | Series A | 0 |
| 4/2013 | Allecra Therapeutics | Series A | 19.6M |
| 6/2016 | Allecra Therapeutics | Series B | 24.8M |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 4/2018 | Crescendo Biologics | Series B | 0 |
| 4/2017 | Arsanis | Series D | 0 |
| 1/2017 | Luxendo | Series A | 0 |
| 6/2016 | Allecra Therapeutics | Series B | 0 |
| 3/2016 | Topas Therapeutics | Series A | 0 |
| 10/2015 | Luxendo | Series A | 0 |
| 6/2015 | Vira Therapeutics | Series A | 0 |
| 10/2014 | ImevaX | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
